Poor
Needs Major Revision
Patient Risk:
Moderate
Summary
The AI response makes many claims about generic availability, patent expiry, pricing, dosage strengths, manufacturers, switching, and bioequivalence that are not supported by the provided FDA label excerpts. Several indication/mechanism and adverse-reaction statements are overgeneralized from a fixed-dose lisinopril/hydrochlorothiazide excerpt or not supported in the exact scope phrased.
Category Scores
Accurate Statements
Lisinopril belongs to the class of drugs called angiotensin-converting enzyme (ACE) inhibitors.
CLINICAL PHARMACOLOGY (Mechanism of Action) states lisinopril inhibits angiotensin-converting enzyme (ACE).
Lisinopril relaxes blood vessels.
CLINICAL PHARMACOLOGY (Mechanism of Action) describes decreased angiotensin II leading to decreased vasopressor activity (supports vasodilation concept, but not the exact wording).
Relaxing blood vessels with lisinopril helps to lower blood pressure.
CLINICAL PHARMACOLOGY (Mechanism of Action) links ACE inhibition to decreased vasopressor activity and decreased aldosterone secretion, and describes antihypertensive effect; supports lowering blood pressure mechanistically (but not exact phrasing).
Unsupported Statements
Lisinopril is available as a generic medication.
Provided label excerpts do not mention generics.
Lisinopril can be manufactured and sold by multiple companies after its patent protection expires.
Provided label excerpts do not discuss patent status or generic manufacturing/sales.
The patent for lisinopril has long since expired, allowing for the availability of generic versions.
Provided label excerpts do not mention patents or patent expiry.
Generic lisinopril is significantly lower in cost than the brand-name version.
No pricing/cost comparisons are present in provided label excerpts.
The cost of generic lisinopril can vary depending on the pharmacy, dosage, and insurance coverage.
No pricing variability statements are present in provided label excerpts.
Generic lisinopril is generally considered an affordable medication.
No affordability statements are present in provided label excerpts.
Generic lisinopril is available in various dosages.
Provided label excerpts do not list lisinopril dosage forms/strength availability.
Common strengths of generic lisinopril include 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg.
No strength list is present in provided label excerpts.
Lisinopril is primarily used to treat heart failure.
No heart failure indication is present in the provided INDICATIONS AND USAGE excerpt.
Lisinopril makes it easier for the heart to pump blood.
No statement in provided excerpts describes improved cardiac pumping as phrased.
Generic lisinopril, like the brand-name drug, can cause side effects.
Provided excerpts discuss adverse experiences for lisinopril plus hydrochlorothiazide, not generic-vs-brand safety equivalence.
More serious side effects can occur with generic lisinopril.
Provided excerpts reference warnings/adverse events generally, but do not support the statement framed specifically as 'generic lisinopril.'
Numerous pharmaceutical companies manufacture generic lisinopril.
No manufacturer/market information is present in provided label excerpts.
Teva Pharmaceuticals manufactures generic lisinopril.
No company-specific manufacturing statements are present in provided label excerpts.
Mylan (now Viatris) manufactures generic lisinopril.
No company-specific manufacturing statements are present in provided label excerpts.
Sandoz manufactures generic lisinopril.
No company-specific manufacturing statements are present in provided label excerpts.
Patients can generally switch between brand-name lisinopril and generic lisinopril.
No switching guidance (brand-to-generic) is present in provided label excerpts.
Brand-name lisinopril and its generic equivalent are designed to be bioequivalent.
No bioequivalence statement is present in provided label excerpts.
Consulting a doctor or pharmacist before making changes to medication is advisable when switching between brand-name and generic lisinopril.
No label excerpt content provided that supports brand-to-generic switching counseling.
Contradictions
Important Omissions
FDA-label-based dosing/strength and administration instructions for lisinopril (including product-specific dosage guidance, titration, and administration details).
Importance:
Moderate
FDA-label-based approved indications for lisinopril alone (the provided indication excerpt refers to lisinopril and hydrochlorothiazide fixed-dose combination for hypertension).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple non-label-supported claims about generic availability, dosing strengths, and switching/bioequivalence, which could mislead readers about product status or usage; only some mechanism and general adverse-experience concepts are partially supported by excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Major Revision
Primary Issue
Most claims are unsubstantiated by the provided FDA label excerpts, especially those regarding generics/patents/pricing/manufacturers, listed strength dosages, and switching/bioequivalence; additionally, an indication claim for heart failure is not supported by the supplied indication excerpt.
Suggested Improvement
Restrict statements strictly to what is supported by the provided label excerpts (e.g., ACE inhibition mechanism and hypertension indication for the lisinopril/hydrochlorothiazide fixed-dose combination, and adverse-experience details as described for that combination in the excerpts). Remove or clearly qualify any generics/patent/pricing/manufacturer/switching/bioequivalence and strength-list claims unless the corresponding FDA label text is supplied.